Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
By
MedTech Outlook | Friday, April 21, 2023
Molecular diagnostics in the life science space opened up plausible opportunities for blood screening.
FREMONT, CA: Molecular diagnostics has become a fair and potential subject in the life science space in recent years and is anticipated to gain further popularity in the future. It opens up formidable opportunities for transparent and transfusion diagnostics, oncology, and infectious disease testing in the biomolecular space.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
With its strong footprint in identifying infectious diseases, molecular diagnostics holds varied advantages over the use of serology and is often considered a more sensitive approach to allow the detection of lower amounts of infectious agents. This, in turn, offers an induced ability in the life science arena for the detection of infection much earlier than the pre-determined criteria. It aids as a potential source in blood screening, where antibodies and antigens are deployed on a wide scale in detecting contaminated blood samples. This pattern of detection was used much before the discovery and application of molecular diagnostic models for a potential blood screening procedure.
A prolonged time lapse in producing antibodies like seroconversion and the generation of significant amounts of several other antigens has extended the window period for the serology-only tests. That is, the time between infection and the ability to detect infection has become critically longer in the testing pattern.
Furthermore, the molecular diagnostics module is also deployed in facilitating treatment guidance and monitoring, in addition to viral screening and the detection of ailments and microorganisms in the blood. Opting for a real-time polymerase chain reaction (PCR) delivers an effective and simple tool in the life science arena, establishing efficiency in therapies and modifying treatments to suit the appropriate conditions.
Similarly, harnessing nucleic acid sequencing in the sector also assists in identifying and differentiating specific viral strains and plays a crucial role in the case of human papillomavirus (HPV) infection. For instance, certain strains are associated with a non-malignant outcome in the molecular diagnostics space, while several others hold a high correlation regarding the development of chronic syndromes like cervical cancer.
Alongside this, thyroxine-binding globulin (TBG), a popular molecular diagnostic platform, focuses on developing traditional PCR, sequencing patterns, and enabling real-time PCR. Adopting these three patterns aids TBG in designing molecular diagnostics, from high-throughput, low-cost screening solutions to high-resolution, sequencing-based genotyping solutions. Thus, thyroxine-binding globulin has managed to develop in vitro diagnostics (IVD) products in the molecular diagnostics space for human leukocyte antigen (HLA) genotyping, human platelet antigen (HPA) genotyping, and the efficient detection of autoimmune diseases in the life science arena.
More in News
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

However, if you would like to share the information in this article, you may use the link below:
www.medicaltechoutlookeurope.com/news/benefits-of-molecular-diagnostics--nwid-2732.html
